LON:EDEN Eden Research (EDEN) Share Price, News & Analysis GBX 3.72 -0.08 (-2.05%) As of 10:23 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlines About Eden Research Stock (LON:EDEN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Eden Research alerts:Sign Up Key Stats Today's Range 3.70▼ 3.8250-Day Range 3.30▼ 4.2752-Week Range 3.30▼ 6.50Volume163,090 shsAverage Volume1.11 million shsMarket Capitalization£19.85 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries. Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has two products currently on the market: Based on plant-derived active ingredients, Mevalone ® is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops. It is a useful tool in crop defence programmes and is aligned with the requirements of integrated pest management programmes. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally. Cedroz ™ is a bionematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops globally. Cedroz is registered for sale on two continents and Eden's commercial collaborator, Eastman Chemical, is pursuing registration and commercialisation of this important new product in numerous countries globally. Eden's Sustaine ® encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation. Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange Green Economy Mark in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services. For more information about Eden, please visit: www.edenresearch.com .Read More… Receive EDEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eden Research and its competitors with MarketBeat's FREE daily newsletter. Email Address EDEN Stock News HeadlinesTRADING UPDATES: Eden Research in revenue rise; Cordel gets UK dealJanuary 13, 2025 | lse.co.ukEden Unveils the World's First Compounded GLP-1 Rx GummyJanuary 1, 2025 | finance.yahoo.comDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.January 21, 2025 | Brownstone Research (Ad)Research booms at USC-owned island after $1M boost. McMaster: Pritchards is ‘Garden of Eden’November 15, 2024 | yahoo.comMorecambe Eden Project hails milestone after £50m is confirmed in BudgetNovember 11, 2024 | msn.comMorecambe Eden Project relief as £50m levelling up cash confirmed in Budget small printNovember 9, 2024 | msn.comLacey Eden strikes twice as Americans open the Rivalry Series with a rout over CanadaNovember 8, 2024 | msn.comEden rents less affordable amid ongoing housing crisisNovember 8, 2024 | msn.comSee More Headlines EDEN Stock Analysis - Frequently Asked Questions How have EDEN shares performed this year? Eden Research's stock was trading at GBX 3.90 on January 1st, 2025. Since then, EDEN stock has decreased by 4.5% and is now trading at GBX 3.72. View the best growth stocks for 2025 here. How were Eden Research's earnings last quarter? Eden Research plc (LON:EDEN) announced its quarterly earnings data on Tuesday, September, 29th. The company reported ($0.40) EPS for the quarter. Eden Research had a negative trailing twelve-month return on equity of 17.27% and a negative net margin of 38.70%. How do I buy shares of Eden Research? Shares of EDEN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Eden Research own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eden Research investors own include Kromek Group (KMK), Primary Health Properties (PHP), National Grid (NG.L), Cabot Energy (CAB), EPE Special Opportunities (ESO), Marston's (MARS) and Mothercare (MTC). Company Calendar Last Earnings9/29/2020Today1/21/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorBasic Materials Industry Agricultural Inputs Sub-IndustryN/A Current SymbolLON:EDEN CUSIPN/A CIKN/A Webwww.edenresearch.com Phone+44-1285-359555FaxN/AEmployees19Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-1,520,000.00 Net Margins-38.70% Pretax MarginN/A Return on Equity-17.27% Return on Assets-11.29% Debt Debt-to-Equity Ratio1.25 Current Ratio3.80 Quick Ratio2.42 Sales & Book Value Annual Sales£3.94 million Price / Sales5.04 Cash FlowGBX 0.31 per share Price / Cash Flow11.90 Book ValueGBX 2 per share Price / Book1.86Miscellaneous Outstanding Shares533,350,000Free FloatN/AMarket Cap£19.85 million OptionableNot Optionable Beta0.92 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (LON:EDEN) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eden Research plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Eden Research With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.